Wendy Naimark, PhD, Chief Technology Officer, Ripple Therapeutics
Dr, Naimark is one of the founders of Ripple Therapeutics (RIPL) following its spin out from Interface Biologics (IBI) in 2020. Dr. Naimark has been leading teams in the development of local drug delivery products for over 20 years. She joined IBI in 2016 and led the Research & Development of both Epidel and Kinesyx technology teams and partner projects. Prior to joining IBI, Dr. Naimark led the Clinical Program for the development of a drug-eluting, self-expanding, biodegradable scaffold at 480 Biomedical (founders: Drs. Bob Langer (MIT) and George Whitesides (Harvard)).
Dr. Naimark began her industry career at Boston Scientific in the Corporate R&D group, which developed the TAXUS® Drug Eluting Stent. At Boston Scientific her work spanned developing combination products to deliver angiogenic biological agents to leading Regulatory Submission Strategies for approval of Class III combination products.
Dr. Naimark received her PhD in Biomaterials from the University of Toronto and began developing her career interest in local drug delivery at Caltech during her post-doctoral fellowship. Dr. Naimark is an inventor of 30 patents in the local drug delivery field.
Women in Clinical Trials & Life Sciences: International Women’s Day 8 March 2023
- Discuss historical to present day underrepresentation of women in clinical trials
- Review of implications on health outcomes due to underrepresentation of women
- Explore strategies for improved inclusion of women in clinical trial
- Sharing a framework for creating a successful business
- Discovering the importance of team development and shared values
- Learn how to run a large scale international clinical trial when you are a small size Canadian biotech company
- Discover strategies to build a body of clinical and scientific evidence when funds are limited